Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Price Website

Douglas K. Price, Ph.D.

Selected Publications

1)  Roth JE, Peer CJ, Price DK, Figg WD.
The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples.
Cancer Biol. Ther. 15: 16-8, 2014.
2)  Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.
Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?.
BMJ Open. 3, 2013.
3)  Hall C, Troutman SM, Price DK, Figg WD, Kang MH.
Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.
Clin Genitourin Cancer. 11: 10-9, 2013.
4)  Fernández EV, Price DK, Figg WD.
Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease.
Cancer Biol. Ther. 14: 1005-6, 2013.
5)  Johnson LM, Price DK, Figg WD.
Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: implications for potential use of inhibitors in cancer treatment.
Cancer Biol. Ther. 14: 90-1, 2013.
6)  Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.
Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.
Oncologist. 17: 312-20, 2012.
7)  Richardson ED, Price DK, Figg WD.
Significant addition to treatment options for bone metastasis in prostate cancer.
Cancer Biol. Ther. 13: 69-70, 2012.
8)  Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD.
Estrogen receptor a and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
J. Clin. Endocrinol. Metab. 96: E368-72, 2011.
9)  Pressler H, Sissung TM, Venzon D, Price DK, Figg WD.
Expression of OATP family members in hormone-related cancers: potential markers of progression.
PLoS ONE. 6: e20372, 2011.
10)  Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clin. Cancer Res. 17: 937-46, 2011.
11)  Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Cancer Causes Control. 22: 1121-31, 2011.
12)  Price DK, Woodard WL, Teigland CM.
Simultaneous detection of circulating prostate specific antigen (PSA)-expressing and prostate specific membrane antigen (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Urol. Oncol. 1: 226-33, 2011.
13)  Sissung TM, Pressler H, Price DK, Figg WD.
SLCO transport genes in prostate cancer--letter.
Cancer Epidemiol. Biomarkers Prev. 20: 2325; author reply 2326-7, 2011.
14)  Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD.
The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.
Mutat. Res. 708: 21-7, 2011.
15)  English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.
Ther Clin Risk Manag. 6: 579-83, 2010.
16)  Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD.
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.
J. Urol. 184: 2297-302, 2010.
17)  Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R.
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
BMC Cancer. 10: 511, 2010.
18)  Figg WD, Smith EK, Price DK, English BC, Thurman PW, Steinberg SM, Emanuel E.
Disclosing a diagnosis of cancer: where and how does it occur?.
J. Clin. Oncol. 28: 3630-5, 2010.
19)  Gao R, Price DK, Dahut WL, Reed E, Figg WD.
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.
Cancer Biol. Ther. 10: 13-8, 2010.
20)  Kirkland CT, Price DK, Figg WD.
Genetic variant associated with aggressive not indolent prostate cancer.
Cancer Biol. Ther. 9: 957-8, 2010.
21)  Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
J. Exp. Clin. Cancer Res. 29: 95, 2010.
22)  Troutman SM, Price DK, Figg WD.
Prostate cancer genomic signature offers prognostic value.
Cancer Biol. Ther. 10: 1079-80, 2010.
23)  Price DK, Ayres JA, Pasqualone D, Cabell CH, Miller W, Hardison RC.
The 5' ends of LINE1 repeats in rabbit DNA define subfamilies and reveal a short sequence conserved between rabbits and humans.
Genomics. 14: 320-31, 1992.
24)  Price DK, Woodard W, Teigland CM.
Simultaneous detection of circulating prostate-specific antigen (PSA)-expressing and prostate-specific membrane (PSM)-expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Urologic Oncology. 1: 226-233, 1995.
25)  Price DK, Zhang F, Ashley CT, Warren ST.
The chicken FMR1 gene is highly conserved with a CCT 5'-untranslated repeat and encodes an RNA-binding protein.
Genomics. 31: 3-12, 1996.
26)  Price DK, Clontz DR, Woodard WL, Kaufman JS, Daniels JM, Stolzenberg SJ, Teigland CM.
Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay.
Urology. 52: 261-6; discussion 266-7, 1998.
27)  Montgomery JS, Price DK, Figg WD.
The androgen receptor gene and its influence on the development and progression of prostate cancer.
J. Pathol. 195: 138-46, 2001.
28)  Price DK, Ando Y, Kruger EA, Weiss M, Figg WD.
5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
Therapeutic drug monitoring. 24: 104-10, 2002.
29)  Sissung TM, Price DK, Sparreboom A, Figg WD.
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Mol. Cancer Res. 4: 135-50, 2006.
30)  Li H, Price DK, Figg WD.
ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer.
Anticancer Drugs. 18: 563-8, 2007.
31)  Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Prostate. 70: 584-90, 2010.
32)  Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD.
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
The pharmacogenomics journal. 2009.
33)  Figg WD, Woo S, Zhu W, Chen X, Ajiboye AS, Steinberg SM, Price DK, Wright JJ, Parnes HL, Arlen PM, Gulley JL, Dahut WL.
A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer.
The Journal of urology. 2010.
34)  Baum CE, Ockers SB, English BC, Price DK, Sartor O, Figg WD.
Androgen receptor sequence and variations in several common prostate cancer cell lines.
Cancer biology & therapy. 9, 2010.
35)  Baum CE, Price DK, Figg WD.
Sarcosine as a potential prostate cancer biomarker and therapeutic target.
Cancer biology & therapy. 9, 2010.
36)  Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clin. Cancer Res. 15: 1496-503, 2009.
37)  Stein EV, Price DK, Figg WD.
shRNA technology: investigating Ras-dependent cancer.
Cancer Biol. Ther. 8: 1798-9, 2009.
38)  Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.
Mol. Cancer Ther. 8: 2496-508, 2009.
39)  English BC, Price DK, Figg WD.
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Cancer Biol. Ther. 8: 1212-3, 2009.
40)  Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD.
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
BJU Int. 102: 617-21, 2008.
41)  Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD.
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clin. Cancer Res. 14: 4543-9, 2008.
42)  Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD.
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
BJU Int. 102: 1694-9, 2008.
43)  Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A.
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Mol. Cancer Ther. 7: 19-26, 2008.
44)  Li H, Raia V, Bertolini F, Price DK, Figg WD.
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
BJU Int. 101: 884-8, 2008.
45)  Beuten J, Gelfond JA, Byrne JJ, Balic I, Crandall AC, Johnson-Pais TL, Thompson IM, Price DK, Leach RJ.
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians.
Carcinogenesis. 29: 1751-7, 2008.
46)  Chen X, Gardner ER, Price DK, Figg WD.
Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis.
Journal of chromatographic science. 46: 356-61, 2008.
47)  Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clin. Cancer Res. 14: 3312-8, 2008.
48)  Gao R, Price DK, Sissung T, Reed E, Figg WD.
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Mol. Cancer Ther. 7: 1246-50, 2008.
49)  Hoque A, Goodman P, Ambrosone CB, Figg WD, Price DK, Kopp W, Wu X, Conroy J, Lehman TA, Santella RM.
Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.
Urology. 71: 967-70, 2008.
50)  Danish M, Sissung T, Price DK, Figg WD.
Genetic stability of tumor microenvironment.
Cancer Biol. Ther. 7: 331-2, 2008.
51)  Miles RJ, Price DK, Figg WD.
Temporal-mediated FGFR1 independence: implications for targeting candidate molecules in prostate cancer.
Cancer Biol. Ther. 7: 1180-1, 2008.
52)  Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T.
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
Oncologist. 13: 1046-54, 2008.
53)  Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD.
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology. 70: 217-20, 2007.
54)  Aragon-Ching JB, Gillespie J, Price DK, Chuaqui R, Rodriguez-Canales J, Steinberg SM, Dahut WL, Figg WD.
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
BJU Int. 100: 1245-8, 2007.
55)  Ockers S, Price DK, Figg WD.
DNA microarrays: tissue removal and processing affects gene expression.
Cancer Biol. Ther. 5: 1608-9, 2006.
56)  Singh AS, Macpherson GR, Price DK, Schimel D, Figg WD.
Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis.
Oncol. Rep. 15: 519-24, 2006.
57)  Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM.
Influence of Garlic (Allium sativum) on the Pharmacokinetics of Docetaxel.
Clin. Cancer Res. 12: 4636-40, 2006.
58)  Smith EK, Price DK, Figg WD.
Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation.
Cancer Biol. Ther. 5: 1443-4, 2006.
59)  Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clin. Cancer Res. 11: 7398-404, 2005.
60)  Singh AS, Chau CH, Price DK, Figg WD.
Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer.
Nature clinical practice. Urology. 2: 101-7, 2005.
61)  Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, González S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF.
Molecular alterations in primary prostate cancer after androgen ablation therapy.
Clin. Cancer Res. 11: 6823-34, 2005.
62)  Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD.
Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
Cancer Biol. Ther. 4: 1222-5, 2005.
63)  Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McMann MC.
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
J. Urol. 171: S3-4, 2004.
64)  Price DK, Franks ME, Figg WD.
Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
J. Urol. 171: S45-9; discussion S49, 2004.
65)  Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD.
Genotyping and functional analysis of the D104N variant of human endostatin.
Cancer Biol. Ther. 3: 1298-303, 2004.
66)  Price DK, Figg WD.
hTert-immortalized endothelial cells: an important new research tool.
Cell Cycle. 3: 789, 2004.
67)  Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Journal of clinical pharmacology. 44: 854-60, 2004.
68)  Price DK, Figg WD.
Mutations in the EGFR: the importance of genotyping.
Cancer Biol. Ther. 3: 434-5, 2004.
69)  Macpherson G, Ng S, Lakhani N, Price D, Ventiz J, Figg W.
Cher M, Raz A, Honn KK, eds.
Anti-angiogenesis therapeutic strategies in prostate cancer. In: Prostate Cancer: New Horizons in Research and Treatment.
Dordrecht, The Netherlands: Academic Publishing; 2003. p. 317-330 [Book Chapter]
70)  Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD.
Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.
Mol. Cancer Ther. 2: 845-54, 2003.
71)  Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK, Figg WD.
Current status of thalidomide and its role in the treatment of metastatic prostate cancer.
Crit. Rev. Oncol. Hematol. 46 Suppl: S49-57, 2003.
72)  Ando Y, Price DK, Dahut WL, Cox MC, Reed E, Figg WD.
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer Biol. Ther. 1: 669-73, 2003.
73)  Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD.
Antiangiogenesis therapeutic strategies in prostate cancer.
Cancer Metastasis Rev. 21: 93-106, 2002.
74)  Figg WD, Kruger EA, Price DK, Kim S, Dahut WD.
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Investigational new drugs. 20: 183-94, 2002.
75)  Bennett CL, Price DK, Kim S, Liu D, Jovanovic BD, Nathan D, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD.
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status.
J. Clin. Oncol. 20: 3599-604, 2002.
76)  Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon DJ, Liewehr DJ, Johnson ME, Reed E, Figg WD.
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
Urologia internationalis. 68: 16-23, 2002.
77)  Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD.
Approaches to preclinical screening of antiangiogenic agents.
Semin. Oncol. 28: 570-6, 2001.
78)  Asbill KK, Higgins RV, Bahrani-Mostafavi Z, Vachris JC, Kotrotsios SH, Elliot MC, Price DK.
Detection of Neisseria gonorrhoeae and Chlamydia trachomatis colonization of the gravid cervix.
Am. J. Obstet. Gynecol. 183: 340-4; discussion 345-6, 2000.
79)  Meyer RA, Young CG, Meyer MH, Garges PL, Price DK.
Effect of age on the expression of Pex (Phex) in the mouse.
Calcif. Tissue Int. 66: 282-7, 2000.
80)  Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV, Hall JB.
The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer.
Cancer Invest. 18: 722-30, 2000.
81)  Meyer RA, Henley CM, Meyer MH, Morgan PL, McDonald AG, Mills C, Price DK.
Partial deletion of both the spermine synthase gene and the Pex gene in the X-linked hypophosphatemic, gyro (Gy) mouse.
Genomics. 48: 289-95, 1998.
82)  Hardison R, Chao K, Adamkiewicz M, Price D, Jackson J, Zeigler T, Miller W.
Positive and negative regulatory elements of the rabbit embryonic e-globin gene revealed by an improved multiple alignment program and functional analysis.
DNA Sequence-- J. DNA Sequencing and Mapping. 4: 163-176, 1993.
Click Here to View Collapsed Bibliography.

This page was last updated on 3/25/2014.